Bavarian Nordic releases more specific guidance - downgrades expectations

Although Covid-19 has not disrupted sales of Bavarian Nordic's ebola vaccine, its hands are still tied in other business areas, leading the firm to downgrade its financial guidance.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

Bavarian Nordic's potential Covid-19 vaccine has been hogging the spotlight over the past few months, but the company has also been working on its other business areas - where Covid-19 is more of a hindrance than a help.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading